Companies in #Gamma-Delta T Cell Therapy
Found 1 company operating in this sector.
IN8bio is a New York-based clinical-stage biopharmaceutical company developing genetically modified gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for solid and hematologic malignancies. Lead programs include INB-100 (donor-derived γδ T cells for leukemia patients undergoing haploidentical transplant), INB-200 and INB-400 (autologous γδ T cells for glioblastoma), and INB-619, a CD19-targeting γδ T cell engager advancing into IND-enabling studies. The company reported $18.0M in cash at June 30, 2026. Co-founded in 2016 by CEO William Ho and scientific founder Dr. Lawrence Lamb.